PHOTO
•How the market leader for in-vitro diagnostics is heralding a new era with key product launchesof three new solutions
•Continuous learning platform 'Classroom of the Future' featured to offer support and training to medical professions in the UAE and across the Middle East
Dubai - Roche Diagnostics Middle East launched its latest innovations inin-vitro diagnostics today, marking the first day of the Arab Health Exhibition & Congress 2015. The launch featured three new diagnostics solutions- cobas® 8100, cobas t 411 and VENTANA HE 600 system - and the unveiling of a new continuous education platform for lab personnel - the RDME Academy.
"In launching these new products at Arab Health, we've reaffirmed our dedication to the region and reinforced our commitment to providing first class diagnostics solutions- moving forward, our presence in the Middle East should allow us to continue to develop further breakthroughs and innovations," said Moritz Hartmann, General Manager of Roche Diagnostics Middle East. "These new diagnostic technologies were designed to help healthcare professionals deliver smooth, efficient in-vitro diagnostics services, whilst also offering regional patient's added peace of mind, as they can rest assured they are receiving industry-leading dedicated, safe and efficient solutions."
In the Middle East for the first time, the cobas®8100 automated workflow series, is a total lab automation solution that supports central laboratories with its 3D intelligent bi-directional transportation, which supports high-through put sample processing. The solution also provides a wide-range of connectivity options that make it easily adaptable to any laboratory's needs.
Consistent with Roche Diagnostics' current innovations driven by a commitment to deliver customer led, quality-oriented and cost-effective solutions, Roche Diagnosticsis entering a new era of testing solutions for its coagulation customers. The new coagulation analyzer, the cobas t411,was designed to allow maximum flexibility for laboratories with low-to-medium throughput and a unique set of enhanced safety features to ensure robust and high quality patient results, every time. It features innovative sample and reagent management concepts and offers increased operator convenience and productivity.
As Roche Diagnostics shares the vision of healthcare professionals for exceptional patient care and safety, the booth will also exhibit the latest solutions for histopathology laboratories with the VENTANA HE 600. With thissystem, laboratories can rely on fully
automated, consistent high quality hematoxylin and eosin staining with no patient cross contamination in a simpler and more cost-effective and reliable way.
In addition to the key product launches, Roche Diagnostics also showcasedthe 'Classroom of the Future',a continuous learning platform that is part of the RDME Academyand aims to provide healthcare professional withcontinuous training by experts in the field.
As the only in-vitro diagnostics company to offer such a comprehensive learning program, the fully interactive RDME Academy website has attracted the attention of the diagnostics community in the Middle East. With continuous education being an absolute requirement when it comes to cutting edge solutions, specialists at Roche Diagnostics are leading the e-learning platform.
Accessible online to the entire region, classes focus on topics such including Laboratory Topics in Quality, Safety, and Accreditation; Medical Value; Product Knowledge topics; and Advanced system operator trainings, which help ensure that new equipment is properly operated and that medical value of tests and assays is fullyoptimized. More training content is expected to be added in the near future as part of Roche Diagnostics Middle East's commitment to foster and build professional talent within the industry.
With these innovations, Roche Diagnostics maintains its position as a world leader ofinvitro diagnostics. The launch of the RDME Academy further demonstratesthe company's contribution to providing healthcare professionals with theexpertiseto ultimately ensure better patient care.
Visit Roche Diagnostics at Arab Health Exhibition & Congress 2015 at our booth at stand MC 10, Sheikh Maktoum Hall and in the Fujairah Lounge Area.
-Ends-
About Roche Diagnostics Middle East
Roche have taken the unprecedented move of being the first IVD company to have a Management Center and a logistics hub in the Middle East. Roche has extended its ownership of the entire supply chain, quality control and customer support all the way into the centre of the region. This base of operations reinforces the commitment to global Roche Standards and is driven by a full team of vastly experienced specialists offering a complete portfolio of services. With this regional empowerment, Roche has moved its leadership and decision-making closer to its customers and distributors. These investments allow Roche Diagnostics Middle East to develop from being a supplier into becoming the preferred IVD partner for its customers.
About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients.
Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarial and chemotherapy. In 2013 the Roche Group employed over 85,000 people
worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
PR CONTACT:
Mustapha Al Tayech
Hill+Knowlton Strategies
mustapha.altayech@hkstrategies.com
T: +971 4 334 4930
M: +971 56 1076205
© Press Release 2015
